Tetra Provides Update on Veterinary Ophthalmic Clinical Study

Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF) has provided an update on its veterinary clinical trial to evaluate the safety and potential efficacy of its drug in the treatment of eye pain in companion animals with corneal ulcers.

As quoted in the press release:

Following the authorization from Health Canada in 2019, Tetra has invested in the setup of a sterile cannabinoid drug manufacturing suite at the facility in New Brunswick which has been used to manufacture validated batches of sterile PPP003 drug for use in its ophthalmic drug development program. The design of the sterile suite, implementation of cGMPs, and validation of the sterile process was performed by Tetra’s manufacturing and quality compliance staff. The validated batches of sterile drug will be used in the planned clinical trial in companion animals with indolent corneal ulcers, which is expected to begin in 2020. A similar manufacturing process is required for the clinical trials in human patients with eye diseases such as painful dry eye and uveitis.

Click here to read the full press release.